Authors
Latest:
World Lung Cancer Day: Multiple Barriers Result in Low Lung Cancer Screening RatesAlthough lung cancer screening rates are currently low, identifying the obstacles and potential solutions may raise the number of screenings in the United States.
Latest:
BPDCN: Future Directions in CareClosing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.
Latest:
Omidubicel Increases Availability of Allogeneic Stem Cell TransplantChenyu Lin, MD, discusses the significance of a 10-year follow up of a study of patients who underwent allogeneic stem cell transplant with the novel cell therapy omidubicel.
Latest:
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer CareIn this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Advancing the Treatment of Alveolar Soft Part SarcomaIn season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.
Latest:
Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant MelanomaAxel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
Latest:
Discussing Daratumumab’s Ongoing Impact on Multiple Myeloma TreatmentJoseph Mikhael, MD, discusses the ongoing impact of daratumumab in the treatment landscape of patients with multiple myeloma.
Latest:
Discussing the Role of Tivozanib in the Third-Line of RCC TreatmentWith updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.
